or Try an Advanced Search...

    ETF Components for HRTS - Tema Cardiovascular and Metabolic ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    LLY F -0.25 6.44
    VRTX F 0.13 5.64
    AMGN D 1.60 5.11
    ALNY D -0.77 4.95
    CRNX C -1.70 4.00
    BBIO F 0.77 3.69
    CYTK F 3.00 3.47
    BSX B -1.64 2.99
    ASND D 5.85 2.88
    MDT D 1.73 2.79
    MIRM B 2.87 2.60
    DXCM D -2.19 2.57
    MREO F 1.09 2.49
    IONS F 0.21 2.42
    MASI A 2.27 2.39
    REGN F -0.87 2.37
    KROS D 3.86 2.10
    EW C 0.14 1.91
    MLYS F 5.22 1.89
    PODD C 0.35 1.88
    RCKT F 10.32 1.80
    ARWR F 1.42 1.76
    RARE D 2.65 1.71
    NTLA F 3.62 1.66
    MDGL B 5.53 1.46
    WST C -1.34 1.43
    AKRO B 4.90 1.28
    NVS D 0.41 1.26
    VKTX F 1.86 1.14
    NARI C -0.18 0.97
    EWTX C 0.69 0.96
    SLN F -8.72 0.91
    TERN F 1.40 0.70
    VERV F 5.43 0.64
    TNYA C 10.19 0.43
    RANI F 1.96 0.31

    Represented by ETF Holdings

    Keywords: Medicine Biopharmaceutical Biotechnology S&P 500 Diabetes Organ Systems Cholesterol Disease Obesity Amyloid Bone Endocrine System Hypertension Amyloidosis Catheter Clinical Development Heart Failure Hypercholesterolemia Insulin Life Sciences
    Industries: Biotechnology Medical Devices Drug Manufacturers - Major Medical Instruments & Supplies Diagnostics & Research

    Recent News for Tema Cardiovascular and Metabolic ETF & its Holdings

    Date Stock Title
    Nov 23 VRTX 3 Monster Stocks in the Making
    Nov 23 BBIO Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
    Nov 22 LLY Sanofi Plans to Change Hospital Drug-Discount Program
    Nov 22 NVS Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
    Nov 22 NVS Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
    Nov 22 MDT Medtronic acquires Fortimedix Surgical to boost surgical portfolio
    Nov 22 VKTX Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?
    Nov 22 BSX Why Is Boston Scientific (BSX) Up 7.5% Since Last Earnings Report?
    Nov 22 VKTX Viking Therapeutics a new buy at B Riley on lead obesity asset VK2735
    Nov 22 PODD PODD Stock to Gain From Launch of Omnipod 5 With Abbott's CGM in US
    Nov 22 BSX Should You Hold IDEXX Stock in Your Portfolio for Now?
    Nov 22 MDGL Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
    Nov 22 DXCM Here’s Why DexCom (DXCM) Declined In Q3
    Nov 22 AMGN Why Amgen (AMGN) is a Top Value Stock for the Long-Term
    Nov 22 LLY VKTX Stock Loses Over $1B in a Month: How to Play the Stock?
    Nov 22 VKTX VKTX Stock Loses Over $1B in a Month: How to Play the Stock?
    Nov 22 LLY Investing in Pharma Stocks? Check These 3 Things First
    Nov 22 DXCM DexCom and OURA Ink Partnership for Metabolic Health Innovation
    Nov 22 MDT MDT Stock Gains From FDA Approval for Its InPen App
    Nov 22 NTLA Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?
    Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund advisor generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.
    Investment Management Cardiovascular Disease Metabolic Disease Treatment Of Cardiovascular Diseases
    Back to the Main HRTS Page...